Minimum requirement of donor cells to reduce the glycolipid storage following bone marrow transplantation in a murine model of Fabry disease

✍ Scribed by Takayuki Yokoi; Hiroshi Kobayashi; Yohta Shimada; Yoshikatsu Eto; Nobuyuki Ishige; Teruo Kitagawa; Makoto Otsu; Hiromitsu Nakauchi; Hiroyuki Ida; Toya Ohashi

• Publisher: John Wiley and Sons
• Year: 2011
• Tongue: English
• Weight: 229 KB
• Volume: 13
• Category: Article
• ISSN: 1099-498X
• DOI: 10.1002/jgm.1566

✦ Synopsis

Abstract

Background

Fabry disease (FD) is a lysosomal storage disorders characterized by a deficiency of the lysosomal enzyme, α‐galactosidase A. This results in the accumulation of glycolipids, mainly globotriaosylceramide (GL‐3), in the lysosomes of various organs. Although bone marrow transplantation and hematopoietic stem cell‐based gene therapy can offer the potential of a curative therapeutic outcome for FD, the minimum requirement of donor cells or gene‐corrected cells to reduce GL‐3 levels is not known.

Methods

Lethally‐irradiated FD mice were transplanted intravenously with normal bone marrow cells (Ly5.1 positive) mixed with those of FD mice (Ly5.2 positive) at various ratios to investigate the level of engraftment and enzyme activity necessary to effect a reduction in GL‐3 storage.

Results

Chimerism of whole white blood cells of recipients' peripheral blood remained stable at 8 weeks after transplantation, and chimerism of granulocytes, monocytes, B cells and T cells was equal to that of white blood cells. GL‐3 levels were significantly reduced in the lung and heart of animals with a 30% and 50% chimera, respectively. The extent of reduction in these mice was almost identical to that with 100% chimera.

Conclusions

In FD mice, reconstitution with 100% donor cells is not required to obtain a therapeutic effect following bone marrow transplantation. These results suggest that a 30% gene correction might be sufficient to reverse disease manifestations in FD. Copyright © 2011 John Wiley & Sons, Ltd.